Open an account

Avanos Medical

AVNS · NYSE

Price unavailable right now.

No price history for this range.

About AVNS

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company is headquartered in Alpharetta, Georgia and currently employs 2,287 full-time employees. The company went IPO on 2014-10-21. The company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. The company also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.

Employees
2,287
Headquarters
Alpharetta, Georgia
Listed
Oct 21, 2014
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
avanos.com

AVNS key statistics

This section is temporarily unavailable. Refresh to try again.

AVNS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 34.0% on average.

  1. Q2 FY24: reported $0.29 per share against an estimate of $0.2927
  2. Q3 FY24: reported $0.36 per share against an estimate of $0.3611
  3. Q4 FY24: reported $0.42 per share against an estimate of $0.408
  4. Q1 FY25: reported $0.26 per share against an estimate of $0.1836
  5. Q2 FY25: reported $0.17 per share against an estimate of $0.153
  6. Q3 FY25: reported $0.22 per share against an estimate of $0.1224
  7. Q4 FY25: reported $0.29 per share against an estimate of $0.253
  8. Q1 FY26: reported $0.22 per share against an estimate of $0.1428

AVNS news

  • Press releasePRNewswire

    American Industrial Partners Completes Acquisition of Avanos Medical, Inc.

  • Press releasePRNewswire

    Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners

  • Press releasePRNewswire

    Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

  • Press releasePRNewswire

    Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger

  • Press releasePRNewswire

    Are CRBG, EQH, AVNS Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Avanos Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avanos Medical, Inc. - AVNS

  • Press releasePRNewswire

    Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are CZR, AVNS, GBTG Obtaining Fair Deals for their Shareholders?

Similar companies

Companies in the same industry as Avanos Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.